Cardinal Health Buys AdaptHealth Diabetes Unit + Strive Medical for $360M Cash — Home-Care Roll-Up Continues

Cardinal Health (Cardinal Health) just moved deeper into the home-care/DME value chain by signing two tuck-in style deals: it will buy AdaptHealth’s Diabetes Health business and [Strive Medical] (private) for a combined ~$360M in cash. The acquisition is designed to strengthen Cardinal’s [Cardinal at-Home Solutions] platform—especially diabetes supplies—while AdaptHealth frames the divestiture as sharpening focus on its core sleep/respiratory/HME operations.

What happened (and what’s actually in the deal)

Cardinal Health is buying access to diabetes patients through an acquisitions “bridge,” not just inventory

Total purchase price

$360M

All cash, per deal coverage (Reuters) and exhibit coverage in an SEC filing

AdaptHealth diabetes business value

$235M

Cash consideration; subject to customary post-closing net working capital adjustments

Strive Medical scope

20,000+ patients

Strive is described as serving 20,000+ patients (primary deal coverage)

Deal headline economics (what’s verifiable from opened sources in this session)
Acquirer	Target	Cash price	Key scope metric	Key deal mechanics mentioned
Cardinal Health	AdaptHealth — Diabetes Health business	$235.0M	Diabetes supplies/support platform (business carve-out)	Subject to post-closing net working capital adjustments; escrow and indemnification language disclosed in SEC exhibit
Cardinal Health	Strive Medical (private)	Implied $125M	Serves 20,000+ patients annually	Strategic tuck-in into at-Home Solutions (details not fully accessible via sources due to browsing restrictions in this session)
Cardinal Health	Combined	$360M	Diabetes + broader DME footprint	Expected to be accretive to adjusted EPS within 12 months after closing (deal coverage)

Load-bearing limitation: in this session, I could open Reuters (snipped content) and an AdaptHealth SEC 8‑K exhibit page confirming the $235.0M diabetes business consideration and working-capital/escrow/indemnity mechanics, but I could not access HME News/StockTitan pages (403/410). That means Strive Medical’s exact purchase price breakdown and detailed integration language are treated as partially unverified here.

Why this deal works financially (and why it might not)

Accretion logic hinges on Cardinal fixing margins while keeping reimbursement risk contained

The headline story sounds simple—grow at-home diabetes and DME supplies by adding tuck-ins—but the financial reality in home-care is that margins and cash conversion depend on payer mix, reimbursement rates, and operational throughput (fulfillment accuracy, turnaround times, and denial management). Cardinal’s stated “acceleration” is likely mostly a supply-chain + process bet rather than a brand/marketing bet.

Published financial baseline for the acquirer and seller (context for synergy feasibility)
Company	Business model (from company overview)	TTM revenue (data tool)	TTM operating margin (data tool)	TTM net margin (data tool)
Cardinal Health	Medical distribution + services; at-home services exposure through Cardinal at-Home Solutions (company description)	$250.74B	1.41%	0.60%
AdaptHealth	Home medical equipment and chronic therapy; sleep/respiratory + HME + diabetes devices/support (company description)	$3.29B	7.33%	-2.80%

Home-care margin math can break quickly if reimbursement pricing lags device/supply costs. Since I could not retrieve Strive-specific financials in this session, the safest conclusion is: synergy is operational (scale + procurement + fulfillment discipline), but reimbursement/demand risk remains the swing factor.

Supply chain mapping (upstream → platform → patient outcomes)

The real moat is operational: Cardinal is tightening the diabetes/DME fulfillment pipeline across multiple steps

Upstream inputs: diabetes-related devices/supplies (e.g., CGMs/insulin pumps) require reliable procurement, inventory planning, and regulatory/quality controls—then downstream fulfillment depends on tight scheduling and patient-specific training/support.
Platform layer: home-care providers manage equipment delivery, remote monitoring/support (where applicable), and billing/claims. This is where scale can reduce per-patient administrative friction and improve denial management.
Downstream demand: Medicare/Medicaid + commercial chronic-care patients drive the volume. Patient volume growth is largely policy- and incidence-driven; the controllable lever is conversion (onboarding) and adherence (keeping patients on devices/supplies).

Named entities across the supply chain that are directly evidenced by the sources we could access
Layer	Entity (listed/unlisted where relevant)	Link to the deal
Acquirer / fulfillment operator	Cardinal Health	Expands its at-home supplies/services platform by acquiring AdaptHealth diabetes business and Strive Medical (deal coverage)
Seller / adjacent platform (diabetes + other home-care)	AdaptHealth	Diabetes Health business is carved out/sold; SEC exhibit confirms $235.0M consideration with post-close adjustments
Target (private provider)	Strive Medical (private)	Characterized as a DME supplier serving 20,000+ patients; acquired to deepen Cardinal’s at-home footprint (deal coverage)
Regulatory clearing / transaction process	HSR Act / customary antitrust clearance	Closing conditions referenced in AdaptHealth SEC exhibit context

What this signals about home-care consolidation in 2026

Cardinal’s bid pattern matches a broader winner-take-most supply-and-services consolidation

Across home-care, simple “patient count” buys aren’t enough anymore. The assets that compound are the ones that let large operators standardize fulfillment, manage reimbursement, and reduce per-patient service cost while maintaining compliance. Cardinal’s move is consistent with an industry where medical distribution giants keep absorbing DME/home-care capabilities that sit closer to patient endpoints.

Even with limited ability to open secondary outlets in this session, the deal framing (diabetes-focused expansion into at-home solutions) combined with the SEC exhibit’s focus on working-capital/escrow and closing conditions points to a transaction structured like an operational carve-out integration, not a speculative platform bet.

Management + capital allocation implications

AdaptHealth is selling to simplify; Cardinal is buying to add “adjacent patients” to its diabetes spine

AdaptHealth’s positioning (per deal coverage) is portfolio focus: it divests Diabetes Health to concentrate on sleep, respiratory, and HME businesses—implying less corporate complexity and more capital redeployment toward core segments.
Cardinal’s positioning is adjacency: diabetes supplies and diabetes support are natural extensions of a home-care supply platform, likely leveraging existing procurement and distribution capabilities while expanding patient reach.
The SEC exhibit indicates the transaction is sensitive to post-closing net working capital and includes escrow/indemnification, which typically protects buyers against operational normalization surprises.

Key deal terms explicitly supported by opened sources in this session
Topic	What was disclosed	Source evidence
Purchase price / cash	Diabetes business valued at $235.0M cash	AdaptHealth SEC 8‑K exhibit page (opened)
Working capital adjustments	Customary post-closing net working capital adjustment process; escrow for working capital adjustments	AdaptHealth SEC 8‑K exhibit page (opened)
Indemnification escrow	Escrow also includes indemnification obligations	AdaptHealth SEC 8‑K exhibit page (opened)
Closing conditions	HSR waiting period and customary closing conditions; additional employee retention acceptance requirement referenced	AdaptHealth SEC 8‑K exhibit page (opened)

Investor checklist for the next 12–18 months

Watch three milestones: integration execution, working-capital normalization, and reimbursement stability

Integration execution: early signals should appear in segment disclosures for Cardinal’s at-Home Solutions—specifically whether churn/denials change versus pre-deal baselines (not fetched here due to tool/API limits).
Working-capital normalization: because the agreement explicitly uses post-closing net working capital adjustments with escrow, the first few quarters after closing can show whether the seller carve-out metrics were “clean” or required significant true-ups.
Reimbursement and utilization: diabetes device/supply demand can be sensitive to coverage policy and clinical guidelines. Any reimbursement headwind could mute accretion.

Unanswered (due to source access constraints in this session): Strive Medical’s exact revenue/EBITDA or the detailed purchase-price breakdown vs the implied $360M total, and any explicit Cardinal segment reporting guidance tied to this acquisition.